Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02403505 · ClinicalTrials.gov registry record · Phase 1
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
A Phase 1 study of Rectal Cancer, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02403505 is a Phase 1 study of Rectal Cancer that is active but no longer recruiting, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The registered enrollment target is 20 participants, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02403505, a Phase 1 study of Rectal Cancer, is active but no longer recruiting, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
Conditions Studied
Interventions
- BIOLOGICAL CEA protein antigen plus BCG Vaccine Mix for percutaneous use
Study Locations (1)
Maryland
- Medicine Invention Design, Inc. (MIDI) - c/o - IORG0007849 - NPI-1023387701 - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02403505
The ClinicalTrials.gov registry entry for NCT02403505 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which CEA protein antigen plus BCG Vaccine Mix for percutaneous use is the first listed.
NCT02403505 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02403505 about?
NCT02403505 is a clinical study titled "Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer". Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein An...
What is the current status of trial NCT02403505?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-12-28. Estimated completion is 2026-02-28.
What conditions does trial NCT02403505 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT02403505?
The interventions under investigation include: CEA protein antigen plus BCG Vaccine Mix for percutaneous use (BIOLOGICAL).
Who is sponsoring clinical trial NCT02403505?
This trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02403505 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
F-Tryptophan PET/CT in Human Cancers
RECRUITING · Phase 1
-
Ultra-fractionated Radiotherapy for Rectal Cancer
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.